Copied
 
 
2022, DKK
26.05.2023
Bruttoresultat

-37.860'

Primær drift

-69.586'

Årets resultat

-148''

Aktiver

135''

Kortfristede aktiver

118''

Egenkapital

115''

Afkastningsgrad

-52 %

Soliditetsgrad

85 %

Likviditetsgrad

+500%

Resultat
26.05.2023
Årsrapport
2022
26.05.2023
2021
03.06.2022
2020
06.07.2021
2019
12.05.2020
2018
30.05.2019
2017
29.05.2018
2016
04.05.2017
2015
18.05.2016
Nettoomsætning9.931.77819.987.7095.818.9101.890.37839.537.69616.005.67258.855.82510.873.673
Bruttoresultat-37.859.951-14.840.810-47.846.300-47.860.993-17.775.142000
Resultat af primær drift-69.585.948-53.944.292-79.433.433-66.809.172-34.190.368-37.521.5799.371.136-20.770.555
Indtægter af kapitalandele (tilknyttede og associerede) 009.718.51000000
Finansielle indtægter9.840.726303.90024.015.2891.712.8922.318.678980.1721320
Finansieringsomkostninger-9.832.687-200.866.216-48.332.549-6.247.506-1.469.947000
Andre finansielle omkostninger00000-941.920-615.779-647.476
Resultat før skat-153.026.770-251.555.582-94.032.183-71.343.786-33.341.637-37.483.3279.623.831-21.418.031
Resultat-148.345.328-246.055.582-88.580.286-65.840.492-27.974.827-31.993.7247.488.433-16.390.785
Forslag til udbytte00000000
Aktiver
26.05.2023
Årsrapport
2022
26.05.2023
2021
03.06.2022
2020
06.07.2021
2019
12.05.2020
2018
30.05.2019
2017
29.05.2018
2016
04.05.2017
2015
18.05.2016
Kortfristede varebeholdninger00000000
Kortfristede tilgodehavender fra salg og tjenesteydelser 3.091.08957.652.80913.128.4619.010.89510.724.10813.636.76610.954.7375.620.381
Likvider73.127.41433.208.77271.509.86921.727.48329.973.0703.925.84129.455.7222.489.238
Kortfristede aktiver117.500.19390.861.58184.638.33130.738.37840.697.17817.562.60740.410.4598.109.619
Immaterielle aktiver og goodwill4.500.0004.500.0004.500.00000000
Finansielle anlægsaktiver0183.646.3880949.9722.950.8814.617.8061.180.2781.263.841
Materielle aktiver10.487.69314.382.76117.971.5362.444.5381.337.8891.032.907920.289615.257
Langfristede aktiver17.451.504202.679.149407.969.7673.394.5104.288.7705.650.7132.100.5671.879.098
Aktiver134.951.697293.540.730492.608.09834.132.88844.985.94823.213.32042.511.0269.988.717
Aktiver
26.05.2023
Passiver
26.05.2023
Årsrapport
2022
26.05.2023
2021
03.06.2022
2020
06.07.2021
2019
12.05.2020
2018
30.05.2019
2017
29.05.2018
2016
04.05.2017
2015
18.05.2016
Forslag til udbytte00000000
Egenkapital115.372.809261.741.125458.250.1127.773.841-63.607.475-36.731.624-5.013.670-12.667.782
Hensatte forpligtelser00000000
Langfristet gæld til banker00000000
Anden langfristet gæld7.270.40412.747.605520.1780000
Leverandører af varer og tjenesteydelser8.861.67915.961.18711.109.57121.424.2455.263.8293.937.4994.837.1992.119.524
Kortfristede forpligtelser14.600.34124.529.20121.610.38024.821.93526.890.4267.737.89812.497.6773.640.787
Gældsforpligtelser19.578.88831.799.60534.357.98626.359.047108.593.42359.944.94447.524.69622.656.499
Forpligtelser19.578.88831.799.60534.357.98626.359.047108.593.42359.944.94447.524.69622.656.499
Passiver134.951.697293.540.730492.608.09834.132.88844.985.94823.213.32042.511.0269.988.717
Passiver
26.05.2023
Nøgletal
26.05.2023
Årsrapport
2022
26.05.2023
2021
03.06.2022
2020
06.07.2021
2019
12.05.2020
2018
30.05.2019
2017
29.05.2018
2016
04.05.2017
2015
18.05.2016
Afkastningsgrad -51,6 %-18,4 %-16,1 %-195,7 %-76,0 %-161,6 %22,0 %-207,9 %
Dækningsgrad -381,2 %-74,2 %-822,3 %-2.531,8 %-45,0 %Na.Na.Na.
Resultatgrad -1.493,6 %-1.231,0 %-1.522,3 %-3.482,9 %-70,8 %-199,9 %12,7 %-150,7 %
Varelagerets omsætningshastighed Na.Na.Na.Na.Na.Na.Na.Na.
Egenkapitals-forretning -128,6 %-94,0 %-19,3 %-846,9 %44,0 %87,1 %-149,4 %129,4 %
Payout-ratio Na.Na.Na.Na.Na.Na.Na.Na.
Gældsdæknings-nøgletal -707,7 %-26,9 %-164,3 %-1.069,4 %-2.326,0 %Na.Na.Na.
Soliditestgrad 85,5 %89,2 %93,0 %22,8 %-141,4 %-158,2 %-11,8 %-126,8 %
Likviditetsgrad 804,8 %370,4 %391,7 %123,8 %151,3 %227,0 %323,3 %222,7 %
Resultat
26.05.2023
Gæld
26.05.2023
Årsrapport
26.05.2023
Nyeste:01.01.2022- 31.12.2022(offentliggjort: 26.05.2023)
Beretning
26.05.2023
Dato for ledelsens godkendelse af årsrapporten:2023-05-25
Ledelsespåtegning:2022 was a very unusual year for the biotech industry, as for Saniona. Challenging global developments and markets have impacted the company and our peers. Nevertheless, Saniona has continued to deliver in these volatile times, even though we found it necessary to close our Tesomet Phase 2b study and U. S. operations. I was honored to be offered the position as CEO in April 2022. My first short-term goal was to secure a solid financial runway, independent of dilutive funding. The restructuring of the Group and the renegotiation of the maturity date for an outstanding loan were important components of saving and optimizing the use of the Groups cash position. The Group has thereby reached our target of reducing operating expenses by about 75% and extending the runway by about 18 months. This means that the current cash position is expected to fund the planned activities until the end of January 2024, when the loan becomes payable. We have refocused our efforts on partnering to secure non-dilutive funding, while building long term value from our leading ion channel platform and pipeline. Saniona is a leader in the discovery of highly specific ion channel modulators. Several members of the company’s scientific team have been pioneers in the field for more than 20 years, and we see significant potential in the pipeline and development prospects. I am pleased to report that apart from Tesomet, we have reached all the set milestones and important inflection points for 2022 on our pipeline programs. The Phase 1 clinical trial of SAN711 was successfully completed, SAN903 is ready to enter clinical development and we advanced the preclinical GABAA α2/α3 activator and Kv7 ion channel epilepsy programs. With this solid progress in our pipeline, we see significant potential for multiple value-creating milestones in 2023 including the establishment of partnerships around our programs. This may generate funding for the partnered programs and for internal development programs, while avoiding the need for dilutive financing and dependence on financial markets. We are exploring partnering opportunities on several of our clinical stage and preclinical assets as well as our platform and have had numerous non-confidential and confidential meetings. Many biopharmaceutical companies have entered our program data rooms and we are engaged in constructive discussions about deal structure and financial terms with several potential partners, some of whom are interested in the same program. As a result of these concrete discussions, our current objective is to establishing at least two new partnerships this year, with the aim of concluding at least one by the end of H1. Our short-term objectives from our partnering efforts are to further solidify our balance sheet and finance our internal development programs, thereby enabling us to deliver new valuable breakthrough medicine from our advanced programs in the longer term. We have developed plans for our clinical stage assets and initiated activities to ensure that these programs can be advanced as quickly as possible, as and when we have the resources to develop them internally. Saniona has a broad pipeline of products, a highly motivated and professional team and significant experience with partnering. I am confident that our business development efforts will enable us to move our pipeline forwards, both with external partners and internally, and provide the foundation for delivering valuable new breakthrough medicines. I am proud of what our team has accomplished, and the progress made following the restructuring in 2022. I’m also grateful for the support of our shareholders. We look forward to keeping you updated on our exciting journey in the coming year. The company became part of a group on 30 January 2014, where the parent company, Saniona AB, acquired 100 % of the shares in the company. The group is listed on Nasdaq Stockholm Small Cap. The group’s share is traded under the ISIN code SE0005794617. Saniona A/S established the subsidiary Saniona Inc in January 2020 and owned 100% of the shares in the company. The business in the subsidiary Saniona Inc was closed in April 2022, and the entity was closed in December 2022.
Management's review
Beskrivelse af virksomhedens væsentligste aktiviteter:Saniona is a clinical-stage biopharmaceutical company focused on the discovery and development of medicines modulating ion channels. Saniona’s most advanced candidate, tesofensine, has progressed towards regulatory approval for obesity by Saniona’s partner Medix. Saniona is advancing four product candidates including Tesomet™ and three ion channel modulators SAN711, SAN903 and SAN2219. Tesomet™ has progressed to mid-stage clinical trials for rare eating disorders. SAN711 has completed Phase 1 for neuropathic pain conditions. SAN903 is ready for Phase 1 for inflammatory and fibrotic disorders. SAN2219 is in preclinical development for epilepsy. Saniona has research and development partnerships with Bøhringer Ingelheim GmbH, Productos Medix, S. A de S. V and Cephagenix ApS. Saniona is based in Copenhagen, and listed on Nasdaq Stockholm Small Cap (OMX: SANION). Read more at www. saniona. com.